1161-180 Which is the best pharmacological treatment for obese hypertensive patients with hyperuricemia?  by Masuo, Kazuko et al.
JACC March 3, 2004 ABSTRACTS - Vascular Disease, Hypertension, and Prevention  523A
Vascular Disease, Hypertension, and Prevention
tolic BP, mean arterial pressure (MAP), total cholesterol, HDL, and LDL, between high
and low CRP groups. High CRP patients did however demonstrate higher BMI (+4%;
p=0.02), triglycerides (+13%; p=0.07), %fat (+6%; p=0.01), resting heart rate (+6%;
p=0.004) as well as a lower peak VO2 (-9%; p<0.0001) respectively.
Results: Following CRET, both high and low CRP groups exhibited statistical improve-
ments in %fat (-3.0%, -4.3%), HDL (+7.3%, +7.1%), triglycerides (-12.1%, -8.2%) and
peakVO2 (+11.0%, +8.8%) respectively. Systolic, diastolic and MAP improved in patients
with low CRP but did not change in high CRP patients (Table).
Conclusion: Therapeutic lifestyle change implemented through CRET improves most CV
risk factors. High levels of inflammation, however, appear to blunt the hemodynamic
improvements normally associated with CRET.
1161-178 N-Terminal Pro-Brain Natriuretic Peptide Can Identify 
High and Low Risk Patients With Hypertension and 
Preserved Left Ventricular Systolic Function in the 
General Population
Ilan E. Raymond, Frants Pedersen, Per Rossen Hildebrandt, H:S Frederiksberg Hospital, 
Copenhagen, Denmark
Background: N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) has shown promis-
ing ability to identify subjects with cardiovascular diseases (CV) including hypertension.
The purpose of the study was to evaluate NT-proBNP as a marker of high-risk patients
with hypertension and preserved left ventricular systolic function (LVSF) in the general
population.
Methods: A total of 683 unselected subjects (383 women and 300 men) older than 50
years (mean age 68 + 11 years, range: 50-89 years) from randomly selected general
practitioners filled in a heart failure questionnaire, had an ECG recorded, echocardio-
graphy performed and blood samples taken, and blood pressure and heart rate were
measured. Hypertension was history of hypertension or blood pressure exceeding 150/
90. Preserved LVSF was LVEF<0.50.
Results: 316 subjects fulfilled the criteria of hypertension. Median (range) follow-up was
1145 (51-1197) days, 25 deaths were registered. In a Cox proportional hazards analyses
age, sex, LVEF, systolic and diastolic blood pressures, logNT-proBNP were evaluated as
potential prognostic factors for mortality. LogNT-proBNP (hazard ratio (HR)=8.4,
p<0.0001) and male sex (HR=3.2, p=0.007) was independent markers for mortality. In a
Cox proportional hazards analyses subjects with NT-proBNP above median value (= 33
pmol/l) including the same variables, NT-proBNP (HR=3.3, p=0.045), male sex (HR=2.9,
p=0.01) and age (HR=1.05 per year, p=0.05) were independent markers for mortality.
When raising the cut of value of NT-proBNP with 5% in the analyses, only logNT-proBNP
was a significant predictor of mortality (p<0,0001), independent of age and sex.
Conclusion: In this large sample of the general population, NT-proBNP was a strong
predictor of death within the population suffering from hypertension..
1161-179 Serum Uric Acid and Risk for Development of 
Hypertension: The Normative Aging Study
Todd S. Perlstein, David Sparrow, Scott T. Weiss, Gordon H. Williams, Augusto A. 
Litonjua, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background:Experimental and epidemiological data suggest that uric acid might have a
role in the pathogenesis of hypertension. We sought to examine if uric acid predicts the
risk of developing hypertension in a group of normotensive adult males.
Methods: The Normative Aging Study, established in 1961, is an ongoing longitudinal
cohort of 2280 males initially free of chronic medical disorders such as hypertension.
Comprehensive medical and laboratory evaluations are performed every three to five
years. We used multivariate Cox proportional hazards analysis to determine independent
risk factors for the development of hypertension. Variables considered were serum uric
acid (SUA) level, age, body mass index (BMI), alcohol intake, smoking status, fasting
plasma glucose, total cholesterol, and serum triglycerides. Hypertension was defined as
the examining study physician having recorded a diagnosis of hypertension and either a
blood pressure of greater than 140/90 mm Hg or treatment with anti-hypertensive medi-
cations.
Results: At baseline, the study population had a mean age of 42 ± 9 years, a mean BMI
of 25.6 ± 2.8 kg/m2, and a mean SUA level of 5.8 ± 0.9 mg/dL. In univariate analysis,
SUA level was associated with a risk ratio for hypertension of 1.12 (p = 0.002). Other
univariate predictors were age, BMI, total cholesterol and serum triglycerides. In multi-
variate analyses, SUA level was independently associated with the risk of hypertension
(RR = 1.10, p = 0.03). Other independent predictors were age (p = 0.0001) and BMI (p =
0.0001).
Conclusion: Uric acid level independently predicted the risk of hypertension in this longi-
tudinal cohort of healthy adult males. These data add to the evidence that uric acid might
have a causal role in the development of hypertension.
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Background: It is well-known than obesity and elevated serum uric acid (UA) are risk fac-
tors for cardiovascular diseases, and that weight loss (WL) program is an essential com-
ponent for obesity-hypertension. To know the best way for reducing BP and UA levels in
obese, hyperuricemic, hypertensive (HT) patients, we conducted this study. Methods: 6
groups with 20 obese HT men each were measured BMI, BP, UA, plasma norepinephrine
(NE), insulin and leptin at entry and 12 months. The 6 study groups were matched in age,
BMI, BP and UA at entry. All subjects had hyperUA (>6.5 mg/dL) and non-diabetes
(HbA1c<6.0%). As a significant WL was defined as more than 10% decrease in BMI at
12 months from entry, success rates were 50%** in WL alone, 40%* in ARB+WL, 40%* in
ACEI+WL, 25% in CCB+WL, 15% in alpha+WL, and 10% in beta+WL (*P<.05, **P<.01
vs beta+WL). UA at 12 months were greater in beta+WL > CCB+WL > alpha+WL > WLa-
lone > ACEI+WL > ARB+WL (7.4 mg/dL, 6.8, 6.5*, 6.1**, 5.8**, 5.3**). BP levels at 12
months in pharmacological Tx with failure in WL were lower than in WL alone, and higher
than in pharmacological Tx with success in WL, although BP were similar among the 5
pharmacological Tx groups. Decreases in BMI were greater in WL alone > ARB+WL
>ACEI+WL > CCB+WL > alpha+WL = beta+WL. Decreases in NE were greater in
ARB+WL > ACEI+WL > beta+WL > WL alone > alpha+WL > CCB+WL. Decreases in
insulin were greater in ARB+WL > ACEI+WL > alpha+WL > WL alone > CCB+WL >
beta+WL. Leptin decreased only in subjects with a significant WL. Changes in NE corre-
lated with changes in UA and with changes in mean BP. Changes in insulin correlated
with changes in UA. Conclusions: These results demonstrate that beta- & alpha-blockers
and CCB groups appear to be more resistant to WL and reducing hyperUA compared
with ARB, ACEI or WL alone groups, suggesting that ARB or ACEI should be taken as
the first choice for obesity hypertension with hyperuricemia. WL is an effective treatment
for obesity hypertension with hyperuricemia. Suppression of sympathetic overactivity and
hyperinsulinemia appears to be major roles in the mechanisms of lowering serum UA in
obese hypertensives.
1161-181 Regular Exercise Improves Risk Profile and Motor 
Development in Early Childhood
Kerstin S. Ketelhut, Iman Mohasseb, Christiane Scheffler, Reinhard G. Ketelhut, 
Universität Potsdam, Berlin, Germany, Humboldt-Universität, Berlin, Germany
Even in young children a weakened motor development paralleled by impaired cardiovas-
cular risk profile can be obeserved in industrialized countries. Therefore 3year old chil-
dren were included in a prospective, controlled 2-year intervention study to assess the
efficacy of a regular exercise program (3x a week) on blood pressure (BP), heart rate
(HR), body mass index (BMI) and motor skills.
Methods: 160 children out of a total of 265 (aged 3.5 years) in 17 nursery schools in
Germany participated in a regular exercise program. 105 comparable subjects served as
controls. BP and HR were evaluated at rest by standardized procedures. BMI was calcu-
lated by body-weight and hight. Standardized motor testing included jumping, running,
balance and coordination skills.
Results: Before intervention there were no significant differences between the groups in
all measurements and tests. So far, after one year of intervention, no difference could be
observed in BMI between interventions (I) and controls (C). In contrast, HR which is
known to decrease with age, decreased more in I (7.4%) than in C (5.8%) (p<0.05). This
was true for diastolic BP as well with a tendency towards lower systolic BP, respectively.
Furthermore, the intervention group came off better in all motor tests, with significant dif-
ferences (p<0.001) in such as balance (180cm vs. 130cm) and coordination tests (23.2
points vs.16.7 points).
Conclusion: The study provides evidence that regular exercise improves motor develop-
ment in early childhood due to one year of regular exercise. Moreover, these findings are
paralleled by positive influence on cardiovascular risk factors such as BP and HR. There-
fore, regular physical exercise should be started in early childhood before the first health
deficits and risk profile become evident.
1161-182 Treatment Patterns for Hypertension, Dyslipidaemia, 
and Both Conditions in the United Kingdom: 1997 to 
2001
T. M. MacDonald, S. V. Morant, Christine Baker, Essy Mozaffari, University of Dundee, 
Dundee, United Kingdom
Background: Little is known about the incidence and treatment rates of hypertension
(HTN), dyslipidaemia (DYS), and particularly concomitant HTN/DYS in the United King-
dom (UK). This study was therefore undertaken to measure the annual incidence rates of
recorded, diagnosed, and treated HTN, DYS, and HTN/DYS in a primary care setting.
Methods: This was a retrospective cohort study using the General Practice Research
Database. A fixed population of 399,933 patients aged >40 years, present throughout (or
died during) 1997 to 2001, and who had a minimum 1-year, lead-in history were studied.
Incident HTN patients had not previously been treated or met the criteria for HTN (sys-
tolic blood pressure [BP] >140 mmHg) prior to January 1 each year but had BP recorded
as >140/90 mmHg, subsequently. Similar analyses for incident DYS (total cholesterol >5
mmol/L or low-density lipoprotein [LDL] cholesterol >3 mmol/L) and concomitant HTN/
DYS were performed. Incident treatment was defined as newly treated patients each
year. Logistic regression was used to model trends in the incidence rates.
Results: Between 1997 and 2001, incident DYS diagnoses rose from 1.2% to 3.6%
(+30% per annum [pa]). Incident HTN diagnoses fell from 2.0% to 1.1% (-14% pa), but
concurrent HTN/DYS rose from 0.8% to 2.0% (+27% pa). Incident DYS drug treatment
rose from 0.8% to 1.8% (+22% pa). Treatment for HTN rose from 2.4% to 2.9% (+5% pa),
Low CRP High CRP
Systolic Diastolic MAP Systolic Diastolic MAP
Pre 139±20 76±14 97±14 136±19 74±12 95±12
Post 134±19 73±13 93±13 136±18 74±13 95±12
% change -3.6% -3.9% -4.1% 0% 0% 0%
p value <0.0001 0.005 <0.0001 ns ns ns
